ArticlePloS one2022
A shallow deep learning approach to classify skin cancer using down-scaling method to minimize time and space complexity.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Skin Cancer Image Classification Using Artificial Intelligence Strategies: A Systematic Review.Journal of imaging · 2024Review
- Lobish: Symbolic Language for Interpreting Electroencephalogram Signals in Language Detection Using Channel-Based Transformation and Pattern.Diagnostics (Basel, Switzerland) · 2024Article
- An Automated Broncho-Arterial (BA) Pair Segmentation Process and Assessment of BA Ratios in Children with Bronchiectasis Using Lung HRCT Scans: A Pilot Study.Biomedicines · 2023Article
- Automated Detection of Broncho-Arterial Pairs Using CT Scans Employing Different Approaches to Classify Lung Diseases.Biomedicines · 2023Article
- Skin Lesion Analysis and Cancer Detection Based on Machine/Deep Learning Techniques: A Comprehensive Survey.Life (Basel, Switzerland) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complex feature characteristics and low contrast of cancer lesions, a high degree of inter-class resemblance between malignant and benign lesions, and the presence of various artifacts including hairs make automated melanoma recognition in dermoscopy images quite challenging. To date, various computer-aided solutions have been proposed to identify and classify skin cancer. In this paper, a deep learning model with a shallow architecture is proposed to classify the lesions into benign and malignant. To achieve effective training while limiting overfitting problems due to limited training data, image preprocessing and data augmentation processes are introduced. After this, the 'box blur' down-scaling method is employed, which adds efficiency to our study by reducing the overall training time and space complexity significantly. Our proposed shallow convolutional neural network (SCNN_12) model is trained and evaluated on the Kaggle skin cancer data ISIC archive which was augmented to 16485 images by implementing different augmentation techniques. The model was able to achieve an accuracy of 98.87% with optimizer Adam and a learning rate of 0.001. In this regard, parameter and hyper-parameters of the model are determined by performing ablation studies. To assert no occurrence of overfitting, experiments are carried out exploring k-fold cross-validation and different dataset split ratios. Furthermore, to affirm the robustness the model is evaluated on noisy data to examine the performance when the image quality gets corrupted.This research corroborates that effective training for medical image analysis, addressing training time and space complexity, is possible even with a lightweighted network using a limited amount of training data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.